KM 1
Alternative Names: KM-1Latest Information Update: 22 Aug 2024
At a glance
- Originator Shenzhen Hua Yao Kang Ming Biopharmaceutical
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 13 Jan 2023 Shenzhen Hua Yao Kang Ming Biopharmaceutical plans a phase I K19017-004 trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in China (Intraperitoneal, Infusion) in February 2023 (NCT05684731)